Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM2 | Q9P1W9 | 7/20 | 0.39 |
| ▸ | PIM1 | P11309 | 7/20 | 0.39 |
| ▸ | PIM3 | Q86V86 | 5/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | F11 | P03951 | 2/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 2/20 | 0.32 |
| ▸ | NOS2 | P35228 | 2/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24427822 | 0.83 | NOS3 (0.42) | CYP2A6HRH1HRH4NOS3NOS2 | |
| SCHEMBL24427364 | 0.80 | CYP2A6 (0.36) | CYP2A6HRH1HRH4NOS3NOS2 | |
| SCHEMBL24427806 | 0.75 | CYP2A6 (0.39) | CYP2A6HRH1HRH4BAZ2B | |
| SCHEMBL17832296 | 0.73 | NOS3 (0.34) | PIM2PIM1PIM3NOS3NOS2 | |
| SCHEMBL24427771 | 0.72 | CYP2A6 (0.36) | CYP2A6HRH1HRH4BAZ2B | |
| SCHEMBL20390886 | 0.70 | CYP2A6 (0.44) | CYP2A6HRH1HRH4NOS3NOS2 | |
| SCHEMBL14511616 | 0.70 | MEN1 (0.44) | CYP2A6HRH1HRH4 | |
| SCHEMBL17832297 | 0.70 | SLC9A1 (0.36) | PIM2PIM1PIM3F11NOS3 | |
| SCHEMBL30564706 | 0.70 | IDO1 (0.50) | PIM2PIM1PIM3 | |
| SCHEMBL24427493 | 0.70 | NOS3 (0.32) | PIM2PIM1PIM3NOS3NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11518766-B2 | Tricyclic compound, preparation method therefor and use thereof | SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD. (CN) | 2022-12-06 | — | — | US | disclosed |
| EP-3998263-A1 | TRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Jemincare Pharmaceuticals Co., Ltd. (CN) | 2022-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11518766-B2 | Tricyclic compound, preparation method therefor and use thereof | TFPI, TFPI2, F11 | PIM2 4168/4885PIM1 3541/4885PIM3 4684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.